BioSpace News Archive

The shareholders in Biotage AB, Reg. No. 556539-3138, with its registered office in Uppsala kommun, Uppsala län, are hereby summoned to the Annual General Meeting, to be held on Wednesday, 28 April 2021.

Harmony™ Transcatheter Pulmonary Valve is First Minimally Invasive Alternative for Patients with Severe Pulmonary Regurgitation Who Have a Native or Surgically-Repaired Right Ventricular Outflow Tract

OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) today reported its consolidated annual financial results for 2020 and provided an update on key achievements, as well as the Company’s outlook for 2021 for its immunotherapies in T-cell vaccines, immuno-oncolog

SignalChem Lifesciences, a clinical-stage company developing novel targeted therapies for oncology, announces a collaboration with Merck, known as MSD outside of the United States and Canada, through a subsidiary, to evaluate the combination of SLC-391, a selective AXL inhibitor developed by SignalChem, with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with advanced non-small cell lung cancer (NSCLC).

T2 Biosystems, Inc. a leader in the rapid detection of sepsis-causing pathogens, announced that it issued inducement awards to eighteen new employees.

CEO Amir Jafri will demonstrate how his FDA Breakthrough Device’s platform-based, subtractive therapy business model optimizes standard of care and shareholder value.

NEOGEN Corporation (NASDAQ: NEOG) announced that, at the conclusion of its sponsorship agreement with the National FFA Organization, the company made a $25,000 donation aimed at supporting agricultural education and fighting the spread of COVID-19.

China Pharma Holdings, Inc. (NYSE American: CPHI) (“China Pharma,” the “Company” or “We”), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China , today announced financial results for the fiscal year ended December 31 , 20 20 .

Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), announced today that it has secured $4 million dollars of expansion capital. This financing significantly strengthens the Company’s balance sheet and supports its progress in the commercialization and sale of recombinant spider silk.

The management of Seneca Biopharma, Inc. and Leading BioSciences, Inc. have each received inquiries regarding Seneca’s special meeting of stockholders that was convened on March 24, 2021 and adjourned to April 9, 2021.